{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:27:08Z","timestamp":1794331628748,"version":"4.9.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007558","name":"Rutgers Cancer Institute of New Jersey","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007558","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.eururo.2025.02.010","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T19:21:52Z","timestamp":1745004112000},"page":"33-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"88","author":[{"given":"Saum","family":"Ghodoussipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Carmen","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Psutka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Sundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brant A.","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.02.010_b0005","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"issue":"6 Suppl 4","key":"10.1016\/j.eururo.2025.02.010_b0010","first-page":"S199","article-title":"The management of BCG failure in non-muscle-invasive bladder cancer: an update","volume":"3","author":"Zlotta","year":"2009","journal-title":"Can Urol Assoc J."},{"key":"10.1016\/j.eururo.2025.02.010_b0015","unstructured":"US Department of Health and Human Services. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. 2018. Docket FDA-2018-D-0342."},{"key":"10.1016\/j.eururo.2025.02.010_b0020","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1200\/JCO.23.00307","article-title":"Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group","volume":"41","author":"Kamat","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder Cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol."},{"key":"10.1016\/j.eururo.2025.02.010_b0030","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2025.02.010_b0035","unstructured":"Rayyan. Faster systematic reviews. https:\/\/www.rayyan.ai\/."},{"key":"10.1016\/j.eururo.2025.02.010_b0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2025.02.010_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2020.08.027","article-title":"Unraveling the mechanism of the antitumor activity of bacillus Calmette-Gu\u00e9rin","volume":"80","author":"Li","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0050","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.02.010_b0055","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2025.02.010_b0060","unstructured":"US National Library of Medicine. Pembrolizumab. US Food and Drug Administration (FDA) approved product information. Revised January 2020."},{"key":"10.1016\/j.eururo.2025.02.010_b0065","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0070","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol."},{"key":"10.1016\/j.eururo.2025.02.010_b0075","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1007\/s00345-021-03716-3","article-title":"Phase I trial of intravesical Bacillus Calmette-Gu\u00e9rin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Gu\u00e9rin treatment","volume":"39","author":"Alanee","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0080","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2023.01.013","article-title":"A phase 1b\/2 study of atezolizumab with or without bacille Calmette-Gu\u00e9rin in patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"Inman","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0085","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0090","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","article-title":"First-in-human intravesical delivery of pembrolizumab identifies immune activation in bladder cancer unresponsive to bacillus Calmette-Gu\u00e9rin","volume":"82","author":"Meghani","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bju.16325","article-title":"The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer","volume":"134","author":"Hayne","year":"2024","journal-title":"BJU Int."},{"key":"10.1016\/j.eururo.2025.02.010_b0100","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.eururo.2025.02.010_b0105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/UPJ.0000000000000517","article-title":"Quality of life in the phase 2\/3 trial of N-803 plus BCG in BCG-unresponsive non-muscle invasive bladder cancer","volume":"11","author":"Chamie","year":"2024","journal-title":"Urol Pract"},{"key":"10.1016\/j.eururo.2025.02.010_b0110","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1748981","volume":"9","author":"Rentsch","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.eururo.2025.02.010_b0115","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.euo.2021.12.006","article-title":"A phase 1\/2 single-arm clinical trial of recombinant bacillus Calmette-Gu\u00e9rin (BCG) VPM1002BC immunotherapy in non-muscle-invasive bladder cancer recurrence after conventional BCG therapy: SAKK 06\/14","volume":"5","author":"Rentsch","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"4 Suppl 11","key":"10.1016\/j.eururo.2025.02.010_b0120","first-page":"3","article-title":"Gemcitabine: metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0125","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0305-7372(03)00097-5","article-title":"Mode of action of docetaxel\u2014a basis for combination with novel anticancer agents","volume":"29","author":"Herbst","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2025.02.010_b0130","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0135","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential intravesical gemcitabine and docetaxel is an alternative to bacillus Calmette-Gu\u00e9rin for the treatment of intermediate-risk non-muscle-invasive bladder cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0140","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0145","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000003977","article-title":"A phase II trial of intravesical gemcitabine and docetaxel in the treatment of bacillus Calmette-Gu\u00e9rin\u2013na\u00efve nonmuscle-invasive urothelial carcinoma of the bladder","volume":"212","author":"Patel","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0150","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus Calmette-Gu\u00e9rin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"DeCastro","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.07.007","article-title":"Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: results of a prospective European Multicentre study at 15 months from treatment start","volume":"40","author":"Hurle","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0160","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/JU.0000000000002778","article-title":"Phase 1\/2 trial results of a large surface area microparticle docetaxel for the treatment of high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"Kates","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0165","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1007\/s13346-020-00868-4","article-title":"Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies","volume":"11","author":"Verco","year":"2021","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.eururo.2025.02.010_b0170","doi-asserted-by":"crossref","first-page":"17535","DOI":"10.3390\/ijms242417535","article-title":"OncoTherad(\u00ae) (MRB-CFI-1) nanoimmunotherapy: a promising strategy to treat bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: crosstalk among T-cell CX3CR1, immune checkpoints, and the toll-like receptor 4 signaling pathway","volume":"24","author":"Alonso","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eururo.2025.02.010_b0175","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 \u00b1 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0180","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.010_b0185","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.eururo.2020.07.009","article-title":"The DaBlaCa-13 study: short-term, intensive chemoresection versus standard adjuvant intravesical instillations in non-muscle-invasive bladder cancer\u2014a randomised controlled trial","volume":"78","author":"Lindgren","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0190","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.22.00470","article-title":"DaBlaCa-13 study: oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial","volume":"41","author":"Lindgren","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0195","unstructured":"Business Wire. UroGen announces unprecedented 82.3% duration of response at 12 months in the ENVISION trial investigating UGN-102 as potentially the first FDA-approved non-surgical treatment for LG-IR-NMIBC [press release]. June 13, 2024."},{"key":"10.1016\/j.eururo.2025.02.010_b0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2015.08.003","article-title":"Therapeutic hyperthermia: the old, the new, and the upcoming","volume":"97","author":"Mallory","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2025.02.010_b0205","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/jso.2930280412","article-title":"The effects of hyperthermia on vascular permeability in experimental liver metastasis","volume":"28","author":"Lefor","year":"1985","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0210","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.semcancer.2016.03.004","article-title":"Effects of hyperthermia as a mitigation strategy in DNA damage-based cancer therapies","volume":"37\u201338","author":"Mantso","year":"2016","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.eururo.2025.02.010_b0215","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/02656736.2014.882021","article-title":"A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer","volume":"30","author":"Inman","year":"2014","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.eururo.2025.02.010_b0220","doi-asserted-by":"crossref","DOI":"10.1080\/02656736.2022.2129103","article-title":"Development and investigation of a novel device with gemcitabine for hyperthermic intravesical chemotherapy","volume":"40","author":"Jing","year":"2023","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.eururo.2025.02.010_b0225","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1080\/02656736.2019.1646929","article-title":"Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate- and high-risk nonmuscle-invasive bladder cancer: a single-institution nonrandomized concurrent controlled trial","volume":"36","author":"Zhou","year":"2019","journal-title":"Int J Hyperthermia."},{"key":"10.1016\/j.eururo.2025.02.010_b0230","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0235","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0240","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0245","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2022.08.003","article-title":"Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial","volume":"83","author":"Tan","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euo.2022.10.008","article-title":"Hyperthermic mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: results of the HIVEC-1 trial","volume":"6","author":"Angulo","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.12.025","article-title":"Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage","volume":"39","author":"Grimberg","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0260","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/JU.0000000000003195","article-title":"Safety, tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder cancer who refused or were unfit for curative-intent therapy: a phase 1 study","volume":"209","author":"Tyson","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2022.02.009","article-title":"The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial","volume":"40","author":"Daneshmand","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0270","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001015816.87470.c9.01","article-title":"P2-01\u2003TAR-200 in patients with bacillus Calmette\u2013Gu\u00e9rin-unresponsive high-risk non\u2013muscle-invasive bladder cancer: results from SUNRISE-1 study","volume":"211","author":"Necchi","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0275","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euros.2024.01.013","article-title":"The safety, tolerability, and preliminary efficacy of a gemcitabine-releasing intravesical system (TAR-200) in American Urological Association-defined intermediate-risk non-muscle-invasive bladder cancer patients: a phase 1b study","volume":"62","author":"van Valenberg","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2025.02.010_b0280","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2025.02.010_b0285","doi-asserted-by":"crossref","unstructured":"Vilaseca A, editor. First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) with select FGFR alterations. European Society for Medical Oncology Congress 2023; 2023; Madrid, Spain.","DOI":"10.1016\/j.annonc.2023.10.110"},{"key":"10.1016\/j.eururo.2025.02.010_b0290","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ymthe.2004.07.002","article-title":"Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium","volume":"10","author":"Ramesh","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.eururo.2025.02.010_b0295","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0300","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0305","doi-asserted-by":"crossref","unstructured":"Tyson MD, Uchio E, Nam J-K, et al., editors. P2-02\u2003Pivotal results from BOND-003: a phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. 2024 American Urological Association Annual Meeting 2024; San Antonio, TX.","DOI":"10.1097\/01.JU.0001015816.87470.c9.02"},{"key":"10.1016\/j.eururo.2025.02.010_b0310","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","article-title":"Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial","volume":"30","author":"Li","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2025.02.010_b0315","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.cgt.7700488","article-title":"Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer","volume":"9","author":"Yamashita","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.eururo.2025.02.010_b0320","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0325","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0330","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2025.02.010_b0335","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13073-022-01056-4","article-title":"Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes","volume":"14","author":"Goel","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.eururo.2025.02.010_b0340","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.euo.2022.03.005","article-title":"Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA","volume":"6","author":"Ward","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.010_b0345","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.02.010_b0350","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/djn267","article-title":"Speeding up the evaluation of new agents in cancer","volume":"100","author":"Parmar","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2025.02.010_b0355","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","article-title":"Flexible trial design in practice\u2014stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial","volume":"13","author":"Sydes","year":"2012","journal-title":"Trials"},{"key":"10.1016\/j.eururo.2025.02.010_b0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243136","article-title":"The need for supportive mental wellbeing interventions in bladder cancer patients: a systematic review of the literature","volume":"16","author":"Bessa","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2025.02.010_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.02.010","volume":"22","author":"Montgomery","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.02.010_b0370","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1912885","article-title":"Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with bacillus Calmette-Gu\u00e9rin (BCG) for the treatment of bladder cancer","volume":"10","author":"Rosser","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.eururo.2025.02.010_b0375","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JU.0000000000002186","article-title":"Primary chemoablation of low-grade intermediate-risk nonmuscle-invasive bladder cancer using UGN-102, a mitomycin-containing reverse thermal gel (Optima II): a phase 2b, open-label, single-arm trial","volume":"207","author":"Chevli","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.010_b0380","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.3390\/jcm10215105","article-title":"Long-term experience with hyperthermic chemotherapy (HIVEC) using mitomycin-C in patients with non-muscle invasive bladder cancer in Spain","volume":"10","author":"Plata","year":"2021","journal-title":"J Clin Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382500123X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382500123X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T21:22:50Z","timestamp":1749676970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382500123X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S030228382500123X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.02.010","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}